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Dysfunctional mitochondrial
bioenergetics and the pathogenesis
of hepatic disorders
Christopher Auger, Azhar Alhasawi, Manuraj Contavadoo and Vasu D. Appanna*
Faculty of Science and Engineering, Laurentian University, Greater Sudbury, ON, Canada
The liver is involved in a variety of critical biological functions including the homeostasis
of glucose, fatty acids, amino acids, and the synthesis of proteins that are secreted
in the blood. It is also at the forefront in the detoxification of noxious metabolites that
would otherwise upset the functioning of the body. As such, this vital component of
the mammalian system is exposed to a notable quantity of toxicants on a regular
basis. It therefore comes as no surprise that there are over a hundred disparate
hepatic disorders, encompassing such afflictions as fatty liver disease, hepatitis, and
liver cancer. Most if not all of liver functions are dependent on energy, an ingredient that
is primarily generated by the mitochondrion, the power house of all cells. This organelle
is indispensable in providing adenosine triphosphate (ATP), a key effector of most
biological processes. Dysfunctional mitochondria lead to a shortage in ATP, the leakage
of deleterious reactive oxygen species (ROS), and the excessive storage of fats. Here
we examine how incapacitated mitochondrial bioenergetics triggers the pathogenesis of
various hepatic diseases. Exposure of liver cells to detrimental environmental hazards
such as oxidative stress, metal toxicity, and various xenobiotics results in the inactivation
of crucial mitochondrial enzymes and decreased ATP levels. The contribution of the
latter to hepatic disorders and potential therapeutic cues to remedy these conditions
are elaborated.
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Introduction
As the metabolic hub of the human body, the liver is responsible for the regulation of several
biological processes. Roles undertaken by this organ include the neutralization of toxic substances,
glycogen storage and hormone production along with fat, glucose and alcohol metabolism (Rui,
2014). It acts as the metabolic gatekeeper between the intestines and blood circulation. It also
ensures that toxins are broken down into innocuous compounds to safeguard the organism
from harm. For instance, the versatile enzyme cytochrome P450 participates in the metabolic
deactivation of thousands of endogenous and exogenous compounds such as bilirubin and drugs,
respectively (Chavan et al., 2015). Indeed, exposure to noxious metabolites puts the liver at a greater
risk of injury and dysfunction than other internal organs. Hence, it is not surprising that it is an
organ capable of natural regeneration (Louvet and Mathurin, 2015). Hepatocytes, the functional
units of the liver, make up 70–85% of the mass of this organ and are most susceptible to cellular
damage (Mailloux et al., 2011a). Perturbations in the capacity of these cells to execute the biological
functions of the liver can give rise to cholestatic and fatty liver disease, diabetes and cancer,
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among others (Degli Esposti et al., 2012). In order to avoid these
aﬄictions, hepatocytes require a substantial amount of ATP to
orchestrate its participation in an extensive amount of biological
processes. As such, this universal energy currency is synthesized
at a rate of approximately 30mM/min, with the majority
originating from oxidative phosphorylation (Schmid et al., 2008).
Defective mitochondria and decreased ATP synthesis are the
hallmarks of numerous pathological conditions (Iommarini et al.,
2015; Peralta et al., 2015; Torraco et al., 2015).
Mitochondria are vital organelles that harbor the required
machinery to perform oxidative phosphorylation. The electron
transport chain (ETC), consisting of complexes I–V, couples
electron transport to the synthesis of ATP in the mitochondrial
matrix (Lemire et al., 2009). This aerobic process requires a
reducing component, which comes in the form of the electron
carriers NADH and FADH2. The generation of these moieties
proceeds via the tricarboxylic acid (TCA) cycle, a series of
eight enzymatic reactions also residing in the mitochondrion
(Lemire and Appanna, 2011). Given the diverse functional roles
of the liver, which includes the production of key digestive
compounds, cholesterol synthesis, and ammonia removal,
hepatocytes contain large amounts of mitochondria to fulfill
their bioenergetic demands (Song et al., 2013). In addition, this
organelle plays key parts in intrinsic apoptosis, heme synthesis,
calcium signaling, and β-oxidation, rendering it indispensable to
themodus operandi of the liver (Grattagliano et al., 2011). Hence,
mitochondrial disruption tends to provoke and aggravate liver
disorders such as insulin resistance, hepatocellular carcinoma
(HCC), alcoholic liver disease (ALD), and non-alcoholic fatty
liver disease (NAFLD) (Figure 1) (Galloway and Yoon, 2013).
In this review, we elaborate on the biomolecular events that
orchestrate the pathophysiology of these disorders. These
include the uncontrolled generation of reactive oxygen and
nitrogen species (ROS and RNS, respectively), inactivation
of key transcription factors involved in mitochondrial
biogenesis and anaerobiosis as well as signaling cascades
which trigger apoptosis and necrosis. At the heart of these
biochemical events lies the mitochondrion, the cellular energy
machine, whose proper function governs the well-being of the
liver.
Mitochondrial ROS Production and
Defense
Estimates indicate that approximately 0.2–0.5% of the oxygen
consumed by the mitochondrion is converted into ROS, a
number that is tissue-dependent and varies with the redox state
of the organelle (Chance et al., 1979). Heavy metals, ethanol, and
oxidative stress are known to exacerbate ROS formation (Auger
et al., 2013; Lemire et al., 2014). ROS leakage in the ETC occurs
predominantly at the sites of complex I (NADH ubiquinone
oxidoreductase) and complex III (ubiquinone cytochrome c
oxidoreductase) in the form of superoxide (O•−2 ) (Miwa and
Brand, 2005; Treberg et al., 2011). However, auxiliary sites
of ROS production, such as pyruvate dehydrogenase (PDH),
alpha-ketoglutarate dehydrogenase (KGDH), and succinate
dehydrogenase (SDH), do add to the oxidative burden of this
organelle (Murphy, 2012). Within the mitochondrial matrix,
Mn-dependent superoxide dismutases (MnSOD) are known to
catalyze the dismutation of O•−2 to hydrogen peroxide (H2O2)
that can be readily detoxified by glutathione peroxidase (GPX)
(Wallace et al., 2010). However, if the concentration of H2O2
is not controlled, it diffuses to the cytoplasm and participates
in a series of reactions generating other reactive compounds,
such as hydroxyl radical (•HO). The indiscriminate nature of
•HO, which reacts with lipids, nucleic acids, and amino acids,
renders it short lived but highly dangerous in biological systems
(Imlay, 2013). Furthermore, the diffusion-limited reaction of
O•−2 with the gaseous signaling compound nitric oxide (NO
•)
forms peroxynitrite (ONOO−) (Auger and Appanna, 2015).
The generation of this oxidant and nitrating agent can have
potentially toxic ramifications via the nitration of tyrosine
residues and s-nitrosylation of cysteine moieties on vital proteins
in the mitochondrion (Pacher et al., 2007). Moreover, exposure
to bioavailable cationic metals such as Al and Zn can lead to
an increase in ROS and displace Fe from the active site of some
proteins, such as aconitase (ACN) (Lemire et al., 2008; Han et al.,
2013). Free Fe poses a threat to cells due to its participation in
Fenton chemistry, which further increases the concentration of
detrimental •HO (Ahlqvist et al., 2015).
Nitro-oxidative stress occurs when the production of these
radicals is in excess of the ability of the cell to limit their
reactivity. Given that the majority of cellular ROS is generated
in the mitochondrion, which houses high-priority targets of
these moieties, this organelle requires an intricately-regulated
antioxidant system (Song et al., 2013). The aforementioned
MnSOD, in tandem with mitochondrial glutathione (mGSH) as
well as glutaredoxin and thioredoxin systems are responsible for
limiting the accumulation of O•−2 and H2O2. GSH, which is
synthesized in the cytosol and imported into the mitochondrion,
reduces peroxide concentrations with the assistance of GPX,
or peroxiredoxin, subsequently producing oxidized glutathione
(GSSG) (Mari et al., 2009). The latter is converted back into GSH
via NADPH-dependent glutathione reductase, thus maintaining
the GSH redox cycle. The pool of mGSH represents 10–
15% of the total cellular GSH content (Ribas et al., 2014).
GSH renewal is assured by a number of NADPH-generating
enzymes in the mitochondrion, including malic enzyme (ME),
NADP-dependent isocitrate dehydrogenase (ICDH), and a
matrix-localized glucose-6-phosphate dehydrogenase (G6PDH)
(Figure 2) (Mailloux and Harper, 2010; Yin et al., 2012a). In
humans, the absence of various metabolic strategies aimed
at neutralizing oxidative stress that are operative in other
organisms gives rise to ineffective mitochondrial enzymes and
disease can ensue (Chenier et al., 2008; Mailloux et al.,
2011b).
Mitochondrial ROS and RNS Targets
When the production of radical compounds outmatches
the ability of antioxidants to scavenge them, a number of
biomolecules within the mitochondrion are at risk. Superoxide,
the organelle’s inherent ROS species, reacts primarily with
iron–sulfur (Fe–S) clusters in the absence of NO•. Fe–S
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FIGURE 1 | Mitochondrial dysfunction and disease pathogenesis. Impaired bioenergetics and increased superoxide leakage stemming from a faulty electron
transport chain can initiate and promote the progression of multiple liver disorders. ATP, adenosine triphosphate; ROS, reactive oxygen species.
FIGURE 2 | Nitro-oxidative stress production and detoxification.
Within the mitochondrion, superoxide from electron transport chain activity
can be readily converted to peroxide or react with nitric oxide to form
peroxynitrite. To limit peroxide diffusion and synthesis of the hydroxyl radical,
organisms maintain a pool of mitochondrial glutathione, whose renewal is
orchestrated by glutathione reductase with the help of various
NADPH-generating enzymes. ETC, electron transport chain; G6PDH,
glucose-6-phosphate dehydrogenase; GPX, glutathione peroxidase;
GR, glutathione reductase; GSH, reduced glutathione; GSSG, oxidized
glutathione; ICDH, NADP-dependent isocitrate dehydrogenase; ME, malic
enzyme; MnSOD, manganese superoxide dismutase; NADPH, reduced
nicotinamide adenine dinucleotide phosphate; NOS, nitric oxide synthase.
cluster-containing proteins in mitochondria include ACN, SDH,
fumarase (FUM), and complex I (James et al., 2012). Interference
with the catalytic ability of these proteins affects the flux of carbon
through the TCA cycle, thus diminishing NADH production
and subsequently, ATP synthesis (Mailloux et al., 2006). Other
enzymes that are amenable to redox reactions include the lipoic
acid-containing subunits (E2) of KGDH and PDH (Ambrus et al.,
2009; Auger et al., 2011). Under pathological conditions, ROS
and RNS inhibit the activities of MnSOD, glutathione reductase
and glutathione peroxidase, further aggravating the noxious
effects of these radicals (Song et al., 2013). Lipid peroxidation,
a signature reaction of hydroxyl radical, produces cytotoxic lipid
peroxides such as malondialdehyde (MDA). The latter can form
covalent protein adducts and inactivate key enzymes such as
ACN, ATP synthase (complex V), and aldehyde dehydrogenase
(ALDH2) (Doorn et al., 2006).
Nitric oxide, whose conventional physiological role is to
regulate blood flow and hepatic circulation, can react with heme-
containing proteins such as cytochrome c oxidase of the ETC. In
response to oxidative and inflammatory stresses, inducible nitric
oxide synthase is expressed, leading to a spike in NO• levels, an
event linked to the s-nitrosylation of complexes I and IV, as well
as creatine kinase (Gross et al., 1996; Auger and Appanna, 2015).
Furthermore, ONOO− formation stemming from increasedNO•
and O•−2 synthesis can have adverse downstream effects. The
reaction of NADH and ONOO− generates NAD+ and O•−2 ,
thus forming a positive-feedback cycle resulting in an oxidative
environment (Kirsch and De Groot, 1999). Peroxynitrite also
participates in the s-nitrosylation of catalytic cysteine residues
on NADP+-dependent ICDH and thiol oxidation of the adenine
nucleotide translocator (Vieira et al., 2001; Yang et al., 2002).
Oxidative modifications of mitochondrial DNA (mtDNA) can
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TABLE 1 | Examples of mitochondrial DNA mutations and their respective
liver disorders.
Genetic mutation Mitochondrial defect Liver dysfunction*
A193T Cytochrome b Alcoholic liver disease
(Wong et al., 2004)
G263A
C insertion between
311 and 312
T489C
D-loop Hepatocellular carcinoma
(Nishikawa et al., 2001)
A3243G tRNA (LeuUUR) Type II diabetes mellitus
(Kim et al., 2008)
G3842A NADH dehydrogenase
(subunit 1)
Hepatocellular carcinoma
(Yin et al., 2010)
T6787C Cytochrome c oxidase
(subunit 1)
Hepatocellular carcinoma
(Yin et al., 2010)
*Disease manifested by patient at time of study. Other hepatic disorders resulting from
mitochondrial dysfunction may have occurred.
further decrease the production of ATP by the ETC. Proteins
encoded by mtDNA include 13 polypeptides, all of which are
subunits of the oxidative phosphorylation complexes. As mtDNA
lacks protective histones and has a lower rate of DNA repair
activity compared to the nucleus, deletions and modifications
within the mitochondrial genome result in an accumulation
of mutations in proteins of the ETC, thus increasing ROS
production and diminishing energy levels (Begriche et al., 2011).
While it is estimated that each mitochondrion contains 5–10
copies of mtDNA, a number aimed at limiting the mutagenic
properties of ROS and other toxicants, adverse effects become
pronounced when these copies fall below 20–40% of basal
levels (Bohr and Anson, 1999). Deletions in mtDNA lead to
the development of neuromuscular disorders such as Kearns-
Sayre and Pearson syndrome. One in 4000 children develop
mitochondrial disease by the age of 10. Moreover, mtDNA
mutations may play a role in the pathogenesis of chronic liver
disease (Viscomi et al., 2015) (Table 1).
Liver Mitochondria and Diabetes
Pathogenesis
Diabetes mellitus is a multifactorial metabolic disorder
characterized by insensitivity to insulin, a hormone regulating
the absorption of glucose from blood to bodily tissues. The liver
is a primary target of insulin and glucagon signaling, regulating
glycogen synthesis, and gluconeogenesis in hepatocytes. It
is a well-recognized fact that increased ROS and diminished
mitochondrial ATP production are molecular hallmarks of
type 2 diabetes mellitus (T2DM) (Szendroedi et al., 2012).
Indeed, diabetic patients have higher levels of mitochondrial
protein and lipid oxidation. An increase in mutations and
low concentrations of mtDNA have also been reported. More
specifically, an augmentation in the lipid peroxidation product
4-hydroxynonenal (4-HN) and DNA oxidation biomarker
8-hydroxy-2′-deoxyguanosine in addition to an up-regulated
NADPH oxidase and decreased GSH:GSSG ratio are common
symptoms of the disorder (Noriega-Cisneros et al., 2013).
Lowered activity of complex I/IV as well as MnSOD are signs
of T2DM progression, and likely the result of increased nitro-
oxidative stress affecting key moieties such as Fe-S clusters,
heme groups, and mtDNA coding for ETC components
(Pagano et al., 2014). What remains unclear is whether these
biomolecular events precede, accompany or are a consequence of
the pathogenesis of diabetes. In Otsuka Long-Evans Tokushima
fatty rats, a commonly studied model of obesity and T2DM,
hepatic mitochondrial dysfunction occurs weeks in advance
of the development of insulin resistance. Lower SOD and
increased concentrations of GSSG were detectable at 5 weeks
of age. Decreased activity of carnitine palmitoyltransferase I,
the rate-limiting step of mitochondrial fatty acid entry, was
accompanied by impaired fatty acid oxidation (Rector et al.,
2010). Excess energy intake in the form of over-nutrition leads
to an increase in circulating free fatty acids. As lipid infusion
has been shown to reduce insulin sensitivity, defective lipid
metabolism stemming from mitochondrial disorder appears to
be a key initiator of insulin resistance and subsequently, T2DM.
In the isolated liver, gluconeogenesis, the generation of glucose,
is dependent on mitochondrial fat oxidation. It is noteworthy
that while β-oxidation and ketogenesis are dysfunctional in the
diabetic liver, pyruvate carboxylase, and TCA cycle flux appear
to be elevated. This is in contrast to the mitochondria from
skeletal muscle of diabetic rat models, where TCA cycle activity
appears to be down-regulated. As such, the build-up of NADH
and fatty acid concentrations in conjunction with the lowered
activity of ETC complexes may further compound the ROS
burden, thus bringing about insulin-resistance in the liver of
mammalian organisms (Kim et al., 2008). Hence, mitochondrial
dysfunction coupled with diminished ATP synthesis is an
important contributor to diabetes.
Obesity and NAFLD
With approximately 15–20% of the Western population affected,
NAFLD has become the most common form of chronic
liver disease. This underscores the fact that the number of
children affected by fatty liver has grown exponentially over
the course of the last couple of decades (Wieckowska and
Feldstein, 2005; Nassir and Ibdah, 2014b). NAFLD is diagnosed
when hepatic fat content exceeds 5% of the liver’s total
weight in the absence of significant alcoholic intake, viral, and
autoimmune components (Nassir and Ibdah, 2014b). The widely
accepted hypothesis invoked for the development of NAFLD
is the two hits model, whereas the first hit is a metabolic
disorder such as insulin resistance and hyperlipidemia. The
second hit involves environmental or genetic factors which
trigger mitochondrial dysfunction (Tilg and Moschen, 2010).
Analogous to the pathogenesis of T2DM, the initial biological
events leading to NAFLD are an increase in mitochondrial
ROS, defective ATP generation, and deficiencies in β-oxidation
(Mantena et al., 2008). In NAFLD models, accumulation of
lipid peroxidation and inactivation of key enzymatic entities
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FIGURE 3 | Defective mitochondrial processes underlying liver
disorders. An increase in ROS resulting from the electron transport
chain defects or environmental factors can have detrimental effects
on ATP production and β-oxidation, biomolecular events that trigger the
development of liver diseases. ALD, alcoholic liver disease; ATP,
adenosine triphosphate; BBOX, gamma-butyrobetaine dioxygenase;
CPT, carnitine palmitoyltransferase I; ETC, electron transport chain;
GSH, reduced glutathione; GSSG, oxidized glutathione; KG,
alpha-ketoglutarate; NAFLD, non-alcoholic fatty liver disease; ROS,
reactive oxygen species.
in the mitochondrion leads to ROS-induced oxidative damage
to cardiolipin, a vital phospholipid in the inner mitochondrial
membrane. Cardiolipin is necessary for the functioning of ETC
complexes as it plays a role in the folding and structures
of these moieties (Paradies et al., 2002). As these defects
begin to worsen, mitochondrial morphology, and concentration
is altered drastically. Electron microscopy in mouse models
reveals lowered levels of mitochondria which are swollen and
contain paracrystalline inclusions (Wei et al., 2008). Tumor
necrosis factor-α (TNF-α), a common cytokine involved in
systemic inflammation, plays a role in perturbing mitochondrial
morphology and function. TNF-α is elevated in the bloodstream
of patients with NAFLD and liver tissue of obese mice, where
it is known to induce mitochondrial swelling and perturbations
(Hui et al., 2004). The latter leads to defects in ETC activity,
either directly or via mtDNA damage, thus decreasing ATP
production by liver mitochondria, a phenomenon accompanied
by increased oxidative burden (Sanchez-Alcazar et al., 2000).
Furthermore, TNF-α has been shown to induce hypoxia-
inducible factor-1α (HIF-1α), thus promoting a hypoxic
environment and lowered oxidative energy synthesis (Begriche
et al., 2006).
The detrimental effects of ROS and RNS within the
mitochondria trigger various metabolic changes that limit the
production of reducing factors and ATP in the liver. Defective
MnSOD and a diminished GSH:GSSG ratio initiate the adoption
of novel strategies to limit the accumulation of ROS (Thomas
et al., 2015). The down-regulated activities of PDH and KGDH
brought about by oxidation of the E2 subunit lead to an
accumulation of alpha-ketoglutarate (KG) and pyruvate. This
pool of keto acids serves as an antioxidant in situ, reacting
non-enzymatically with H2O2 to produce the organic acids
succinate and acetate, respectively (Mailloux et al., 2011a; Lemire
et al., 2014). While this stratagem alleviates the oxidative burden
in hepatocytes, it also has wide-ranging implications for fat
oxidation. L-carnitine, an essential metabolite which shuttles
fatty acyl compounds to the mitochondrial matrix for further
breakdown, is formed via four enzymatic steps in biological
systems. The final reaction of carnitine biosynthesis, catalyzed by
gamma-butyrobetaine dioxygenase (BBOX), is reliant on KG. As
the latter is employed to combat oxidative stress, the formation
of carnitine is diminished, which leads to an accumulation
of fatty acids. Indeed, the activity of BBOX in hepatocytes is
lowered by exposure to the stress of H2O2 and metal toxicity
(Figure 3) (Lemire et al., 2011). Supplementation of KG to
injured cells restores the ability to oxidize palmitic acid, further
demonstrating the contribution of nitro-oxidative stress to the
pathogenesis of obesity and NAFLD (Lemire et al., 2011). The
elevated amounts of succinate in the cytoplasm induced by the
KG-propelled detoxification of ROS results in the stabilization
of hypoxia inducible factor 1-alpha. This promotes anaerobiosis,
enhanced glycolysis, and fat accumulation (Mailloux et al.,
2009).
As the effects of lowered aerobic metabolism and fat oxidation
in addition to increased oxidative stress begin to compound,
cellular apoptosis become activated to eliminate damaged cells.
In liver cells, mitochondrial dysfunction triggers the intrinsic
apoptotic pathway, releasing cytochrome c into the cytosol.
Within the mitochondria, the interplay between the anti-
apoptotic proteins Bcl-2 and Bcl-xL and the pro-apoptotic
proteins Bax and Bak dictate the initiation of cell death (Cory
and Adams, 2002). Diminished ATP lowers mitochondrial ability
to maintain its structure and function, leading to the activation of
mitochondrial permeability transition pore. Inability to prevent
cell death in NAFLD ultimately culminates into advanced fibrosis
and cirrhosis of the liver, underscoring the significance of
alleviating mitochondrial dysfunction to slow the pathogenesis
of this disorder (Paradies et al., 2014).
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Alcoholic Liver Disease
According to theWorld Health Organization, acute and excessive
consumption of alcohol contributes to approximately 5% of
global disease and injury. Chronic alcohol drinkers are at risk of
developing ALD, steatohepatitis and eventually, cirrhosis of the
liver. The latter predisposes the patient to the development of
HCC (Rehm et al., 2009). Once in the liver, ethanol is metabolized
via alcohol dehydrogenase (ADH), H2O2-dependent catalase and
cytochrome P450 isoforms. The oxidation of ethanol forms the
highly reactive acetaldehyde, which is capable of forming protein
and DNA adducts, further contributing to tissue damage. While
normally, acetaldehyde is rapidly detoxified by mitochondrial
ALDH, genetic variations in ALDH, and ADH function as well
as increased oxidative stress could inhibit the ability to of the
liver to control concentrations of this moiety (Zakhari, 2006).
Additionally, it has been proposed that acetaldehyde catabolism
increases the pool of mitochondrial NADH, a pro-oxidant
which fuels an ineffective ETC and subsequently increases O•−2
levels (Yu et al., 2010). ALD-affected individuals have enlarged
mitochondria, lowered oxidative phosphorylation, and defective
fatty acid oxidation. Furthermore, increases in ROS and RNS
contribute to deletions and mutations in mtDNA, common
symptoms of the prevalent liver disorders (Nassir and Ibdah,
2014a).
Protein deacetylation, which regulates DNA transcription
as well as enzymatic activity, is controlled by the sirtuin
(SIRT) family. Peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α), which is activated by
deacetylation, is involved in the stimulation of mitochondrial
biogenesis. In rodent models, exposure to ethanol leads
to a decrease in SIRT1, which regulates lipid metabolism
though sterol regulatory element-binding protein-1c as well as
mitochondria biosynthesis through PGC-1α (Fernandez-Marcos
and Auwerx, 2011). Moreover, ethanol exposure seems to induce
the expression of miR-217, a non-coding micro RNA which
further lowers SIRT1 expression and up-regulates the activity
of the lipogenic enzymes acetyl-CoA carboxylase and fatty acid
synthase while lowering β-oxidation by acyl-CoA oxidase (Yin
et al., 2012b).
Hepatocytes from ALD subjects are more susceptible to ROS
and RNS toxicity as well as apoptotic or necrotic cell death,
due to shortages of ATP and increased lipid peroxidation.
To limit such an outcome, the maintenance of mitochondrial
redox state by mGSH is paramount. It is widely accepted
that transport of GSH from the cytosol to the mitochondrion
proceeds via the 2-oxoglutarate carrier, which catalyzes the
electroneutral exchange of KG for malate, or other dicarboxylic
acids (Coll et al., 2003). Changes in mitochondrial membrane
fluidity, such as fluctuations in the cholesterol:phospholipid ratio,
greatly impact the ability of membrane proteins, including those
involved in substrate transport. In alcohol-fed rat livers, the
initial rate of 2-oxoglutarate transport is diminished, negatively
affecting the ability of the mitochondrion to import cytosolic
glutathione. Indeed, increasing the cytosolic concentrations of
N-acetylcysteine, a GSH precursor, does not increase the pool
of mGSH in ALD models. However, preventing the loss of
membrane fluidity with s-adenosylmethionine restores the ability
to transport GSH to the organelle (Mari et al., 2009). Hence,
bolstering the antioxidant capability of the mitochondria may
limit the cytotoxicity of alcohol, enhance ATP production, and
slow the progression to cirrhosis.
Hepatocellular Carcinoma and ATP
Homeostasis
Accounting for approximately three-fourths of primary liver
cancers, HCC is the second leading cause of cancer-related
mortality globally.Whilemany cancers have declined due to early
treatment and preventative measures, the incidence of HCC is
still on the rise, having doubled over the past two decades. Risk
factors for HCC include alcohol abuse, NAFLD and hepatitis B
and C infections (Forner et al., 2012). Rapidly dividing tumor
cells are known to utilize glycolysis as a primary energy source
in lieu of oxidative phosphorylation, even in the presence of
oxygen (Warburg et al., 1927). This phenomenon, known as
the Warburg effect, generally involves mutations in phosphatase
and tensin homolog and Ras that activate phosphoinositide 3-
kinase to increase glucose uptake. Furthermore, oncogenes such
asMyc, which increases glycolytic lactate dehydrogenase, amplify
glucose consumption in an aerobic environment (Brandon et al.,
2006). To promote this lifestyle, dysfunctional mitochondria
are a prerequisite. Indeed, several studies have implicated
mitochondrial disorders in the initiation and progression of HCC
(Warburg, 1956; Lee and Wei, 2009).
There is a large body of literature linking free radicals
and defective antioxidant enzymes to cancer. More specifically,
SOD over-expression can inhibit malignant transformation. The
reduction of MnSOD activity over the life span of a mouse
model correlates to a higher incidence of cancer. Mitochondria-
targeted carcinogens, such as arsenic, promote ROS production,
a biological event conducive to mtDNAmutations and deletions.
In line with what is seen in other cancers, 52% of HCC patients
carry at least one point mutation in tumor tissue mtDNA (Yin
et al., 2010). These genomic alterations in conjunction with a
low mtDNA copy number promote mitochondrial dysfunction
via decreased expression and activity of cytochrome oxidase
and increased electron leakage from the ETC (Nishikawa et al.,
2001). In human hepatoma HepG2 cells, inhibitors of respiration
or mtDNA replication are known to induce mitochondrial
dysfunction and resistance to the chemotherapy drug cisplatin
(Chang et al., 2009). Moreover, certain pathogenic mtDNA
mutations, such as the T8993G transversion, promote tumor
growth by preventing apoptosis (Shidara et al., 2005). As such,
ROS and RNS-mediated mtDNA modifications appear to play a
key role in disabling this organelle and facilitating the transition
to glycolytic energy-production.
In addition to ETC defects, increased oxidative stress wreaks
havoc on the TCA cycle enzymes. As described above, KGDH
inhibition leads to a pooling of KG in the HepG2 cell line.
Non-enzymatic decarboxylation of KGmediated by H2O2 causes
an increase in succinate concentrations (Mailloux et al., 2009).
The decreased activity of SDH observed in several types of
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FIGURE 4 | HIF-1α stabilization is facilitated by elevated succinate
levels. An increase in mitochondrial nitro-oxidative stress impedes
alpha-ketoglutarate dehydrogenase functionality, which leads to the
pooling of alpha-ketoglutarate. The latter scavenges peroxide with
the subsequent formation of succinate, an inhibitor of HIF prolyl
hydroxylases. This stabilizes HIF-1α, protecting it from proteasomal
degradation and allowing it to promote hypoxic conditions in the
nucleus. HIF-1α, hypoxia-inducible factor; KG, alpha-ketoglutarate;
NAFLD, non-alcoholic fatty liver disease; PHD, prolyl hydroxylase;
ROS, reactive oxygen species.
cancer further contributes to the accumulation of this TCA
cycle intermediate (Kim and Dang, 2006). Under normoxic
conditions, HIF-1α is rapidly degraded by prolyl hydroxylases
(PHDs). By hydroxylating proline residues in the oxygen-
dependent degradation domain, PHDs induce the proteosomal
breakdown of this oxygen sensor. Succinic acid interferes with
the activity of PHDs by perturbing substrate-binding sites within
the enzyme, a molecular event which favors HIF-1α stability
and subsequently promotes hypoxia via the nuclear localization
of HIF-1α (Figure 4) (Mailloux and Appanna, 2007). While in
other liver disorders, the dearth of ATP, defective β-oxidation and
increased oxidative burden triggers apoptotic pathways and cell
death, over-activation of anti-apoptotic mediators such as BcL-
X(L), Mcl-1, c-IAP1, and XIAP seen in HCC ensure cell survival
and encourages tumor growth (Hoenerhoff et al., 2011).
Therapeutic Cues
Despite the variance in phenotype stemming from the plethora
of liver disorders, there exists a significant overlap in the
biomolecular pathogenesis at the mitochondrial level. Defective
oxidative phosphorylation, increased ROS and RNS, diminished
β-oxidation, and enhanced lipogenesis are some of the recurring
commonalities across the spectrum of hepatic diseases.
Therefore, mitigating the oxidative burden and bolstering the
mitochondrion’s capacity to produce ATP and break down
fatty acids can have significant health benefits. The interplay
between mitochondrial function and mitochondrial biogenesis
suggests that increasing the number of this organelle can
alleviate the symptoms of mitochondrial disorders. Indeed,
treatment with thiazolidinediones, synthetic peroxisome
proliferator-activated receptor gamma (PPAR-γ) ligands, has
been reported to improve insulin resistance partially through
increased mitochondrial biogenesis (Bogacka et al., 2005). The
antidiabetic drug metformin has also been reported to increase
mitochondrial numbers through activation of PGC-1α and
adenosine monophosphate kinase (AMPK) signaling, while also
lowering ROS concentrations (Kim et al., 2008).
Mitochondria-targeted antioxidants can also be exploited for
the remediation of liver disorders. For instance, the beneficial
effects of vitamin E and C supplementation on tempering ROS
levels are well described (Nassir and Ibdah, 2014b). The ONOO−
scavengermetalloporphyrin has positive effects onmitochondrial
redox state, as demonstrated by restored activity of ALDH2 and
ATP synthase (Moon et al., 2008). Treatment with resveratrol, a
polyphenolic antioxidant found in grapes, can prevent high fat
diet-induced steatosis through regulation of metabolic regulators
of energy such as SIRT1 and AMPK (Poulsen et al., 2012). Keto
acid supplementation in the form of KG or pyruvate can relieve
nitro-oxidative stress directly via their antioxidant properties
while restoring other mitochondrial functionalities indirectly.
For example, KG treatment in HepG2 cells increases levels of L-
carnitine and restores mitochondrial β-oxidation (Lemire et al.,
2011). Pyruvate supplementation drives the pyruvate carboxylase
and ME reactions, thus augmenting levels of NADPH and
mitochondrial citrate. The latter eﬄuxes to the cytosol and
suppresses phosphofructokinase activity, diverting glucose to
the production of NADPH via the pentose phosphate pathway.
The end result of this metabolic reconfiguration is an increased
GSH:GSSG ratio, a parameter leading to reduced oxidative
damage. Indeed, pyruvate supplementation suppresses mtDNA
damage and protein degradation (Tanaka et al., 2007; Liu et al.,
2011).
While supplements may slow the progression of liver disease,
preventative measures such as reduced caloric intake, exercise,
and lower alcohol consumption are key factors in restoring
mitochondrial ability. Exercise and physical activity has been
shown to improve mitochondrial function and insulin sensitivity
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FIGURE 5 | Therapeutic cues aimed at mitochondrial restoration.
Pharmaceutical compounds which increase mitochondrial biogenesis
and mitochondria-targeted antioxidants geared to diminishing the
nitro-oxidative burden can be applied to reverse the molecular events
underlying the pathogenesis of liver disorders, renewing the function of
this crucial organ. ATP, adenosine triphosphate; ETC, electron transport
chain; GSH, reduced glutathione; GSSG, oxidized glutathione;
ROS, reactive oxygen species.
in T2DM patients and subjects with NAFLD. Aerobic exercise
may stimulate mitochondrial biogenesis through increased
expression of PGC-1α (Kim et al., 2008). Furthermore,
endurance exercise and caloric restriction increase mitochondrial
size, number, and oxidative phosphorylation, thus improving
cellular bioenergetics. Additionally, dietary choices such as
increased consumption of polyunsaturated fatty acids and
antioxidant-containing foods can prevent protein oxidation and
mitochondrial dysfunction (Nassir and Ibdah, 2014b). These
lifestyle decisions ultimately lead to higher oxidative ATP
production, increased fatty acid oxidation and lower hepatic fat
accumulation, thus limiting the pathogenesis of liver disorders.
Conclusion
The pathogenesis of liver disease is a complex and multifactorial
process where environmental and genetic signals converge upon
the organ, causing failure to accomplish its vast biological
functions. While there exists several disparities in the means
by which liver disorders progress and present themselves,
mitochondrial dysfunction is a common link in most hepatic
diseases. The role of this organelle in the aerobic synthesis
of ATP, oxidation of fatty acids and apoptotic signaling
renders it indispensable to cellular function, particularly
in energy-intensive organs like the liver. As such, injury
to mitochondria which give way to dysfunction generally
precedes the development of such disorders as T2DM, NAFLD,
ALD, and HCC. Increased nitro-oxidative stress results in
lipid peroxidation and protein oxidation and consequently,
inactivation of ETC complexes and mtDNA mutations or
deletions. Therapeutic and pharmacological strategies to decrease
the oxidative burden and maintain a healthy mitochondrial
redox state can halt or reverse the progression of various liver
diseases, particularly when combined with healthy lifestyle habits
(Figure 5). As such, mitochondria-targeted treatments which
bolster the ability of this organelle to execute its functions can
be implemented to alleviate liver diseases and thus should be
explored more rigorously for their therapeutic potential.
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